Market research
UGY.F Akciju sabiedriba Grindeks
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 92M
- P/E ratio
- 5.95
- Analyst target
- Not available
- Dividend yield
- 9.2%
- Beta
- 0.42
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 92M
- P/E ratio
- 5.95
- Analyst target
- Not available
- Dividend yield
- 9.2%
- Beta
- 0.42
About
About Akciju sabiedriba Grindeks
Akciju sabiedriba Grindeks, a pharmaceutical company, engages in the research, development, manufacture, and sale of original products, generics, and active pharmaceutical ingredients in Latvia. It operates in two segments, Final Dosage Forms and Active Pharmaceutical Ingredients. The company offers heart and cardiovascular drugs, CNS drugs, and anti-cancer medication therapeutic groups under the Mildronate and Ftorafur names; and Oxytocin, a hormone that is used as a medication to facilitate childbirth. Its final dosage forms portfolio includes solid form products, as well as injections, ointments, and syrups. The company also offers contract manufacturing services of tablets, capsules, ointments, and syrups. It also exports its products to 87 countries, which primarily include the European Union countries, Russia and other CIS countries, the United States, Canada, Japan, and Vietnam. Akciju sabiedriba Grindeks was founded in 1946 and is headquartered in Riga, Latvia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the UGY.F discussion.
5 years, 5 months ago
Akciju sabiedriba Grindeks is currently in a long term downtrend where the price is trading 22.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.7.
Akciju sabiedriba Grindeks's total revenue rose by 13.2% to $43M since the same quarter in the previous year.
Its net income has dropped by 157.8% to $-723K since the same quarter in the previous year.
Finally, its free cash flow grew by 962.7% to $5M since the same quarter in the previous year.
Based on the above factors, Akciju sabiedriba Grindeks gets an overall score of 3/5.